Featured Articles
-
The Need For Better Diversity Data In Trial Benchmarking And Feasibility
8/2/2023
To address regulatory, professional, and ethical aspects in clinical trials, learn why diversity must be taken into consideration during a study’s planning and recruitment phases.
-
7 Industry Leaders Weigh In On Patient Engagement & Recruitment
7/18/2023
Gain insights from leaders representing different facets of the clinical trial ecosystem regarding study activities and industry learnings that encourage successful trial outcomes.
-
Highlights From The 2023 Trialscope Disclose EXTRA User Conference
7/17/2023
Step into the realm of clinical trial transparency and innovation as authors delve into the highlights and key learnings from the 2023 Trialscope Disclose EXTRA User Conference.
-
Decentralized Clinical Trials: Meeting Patients Where They're At
7/12/2023
Discover how innovations in DCTs are removing barriers in clinical research and medicine development to improve patient participation.
-
Trial Diversity Needs: How We Got Here & Where We're Headed
7/12/2023
Learn how the representation of underserved populations in clinical trials can be improved with the help of patients, professionals, advocacy groups, and community organizations.
-
Improving Diversity Data In Clinical Trial Benchmarking & Feasibility
6/15/2023
Improving diversity representation in clinical trials relies on demographic data. Get a glimpse of the problems sponsors encounter when obtaining this data and how regulatory agencies are working to ensure its accessibility.
-
2022 Completed Trials: A Roller Coaster Ride For Industry Sponsors
6/15/2023
Dive into this analysis to better understand why the clinical trials landscape has not returned to its pre-pandemic level of momentum.
-
Gene, Cell, & RNA Therapy Landscape: Q1 2023 Data Report
5/18/2023
Get insight from the 2023 first quarter gene, cell, and RNA therapies report composed by Citeline, in conjunction with the American Society of Gene & Cell Therapy (ASGCT).
-
Reimagining The Future: One Chapter At A Time
5/11/2023
Get a glimpse of how the pharmaceutical industry has emerged from the tumultuous episode of the COVID-19 pandemic, stronger and emboldened.
-
Pharma R&D Annual Review 2023 Supplement: New Substances Launched In 2022
5/11/2023
In a sequel to the Pharma R&D Report, the author explores drugs that brought something genuinely new to the world of medicine in 2022 — new active substances (NASs) with some kind of novelty — that just might change the story of patients’ lives.